Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUConn Health
About this trial
The purpose of this research is to determine if two proteins in the blood are increased during acute heart failure. These two proteins are produced when the heart becomes dysfunctional and unable to contract normally. They may then be released into the blood and be detected by standard method in the research laboratory. Thus, the purpose of this study is to determine the relation between the change of these two proteins in the blood and the occurrence of acute heart failure. At this time, detection of an increase in these proteins in the blood is not known to be associated with any disease or heart failure.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Individuals aged >18yrs
stable or decompensated heart failure, irrespective of LVEF
decompensated heart failure clinical symptoms such as dyspnea, rales, edema, elevated jugular venous pressure, or ascites
Imaging evidence of heart failure (cardiomegaly, poor contractile function or echocardiographic Doppler evidence of diastolic dysfunction or elevated right- or left-sided filling pressures)
Disqualifiers
Subjects who are unable to give informed consent
Subjects who had undergone cardiac or non-cardiac surgery in the 3 months before enrollment
Pregnant subjects are not excluded
Trial population
Recruitment will take place in the University of Connecticut Health Center, both hospital inpatients and Cardiopulmonary clinic out-patients. 1. The target population will be heart failure patients of any etiology. We anticipate that 20% of all recruited subjects will be African American and 5% to be Hispanic. This represents the distribution of populations recruited in the past for heart failure studies. 2. Healthy individuals with no prior history of heart attack or heart failure will be recruited to use as controls.
Trial design
Design model
Case-control
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
500 Participants
are grouped into 1 trial groupGroup A: Heart Failure
Trial outcomes
Primary outcomes
1
Hospitalization for acute heart failure, myocardial infarction, stroke or death.
Time frame
3 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
UConn Health
Lead sponsor
CT Department of Public Health
Collaborator
Source ClinicalTrials.gov